Rx00108 - Fluorouracil


Name:
Fluorouracil
Rx ID:
Rx00108
Validation Level:
Phenomic Similarity:
0.561
Reference ID:
DB00544
Primary Indications:
Esophageal carcinoma; glioblastoma multiforme
Orphan Indications:
No annotated orphan indications.
Rare Indications:
No annotated rare indications.
Common Indications:
Colon carcinoma; rectum carcinoma; breast carcinoma; stomach carcinoma; pancreatic carcinoma; actinic keratosis; superficial basal cell carcinoma
Pathways:
Gemcitabine Action Pathway; Gemcitabine Metabolism Pathway
Drug Interactions:
Acenocoumarol; Anisindione; Dicoumarol; Ethotoin; Fosphenytoin; Mephenytoin; Metronidazole; Phenytoin; Tamoxifen; Temsirolimus; ...
Click to show more...
Food Interactions:
Vitamin B1 needs increased with long term use.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00108
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
esophageal carcinoma stomach carcinoma 230 998 1717 541.58 0 0.0
glioblastoma multiforme breast carcinoma 134 2018 22462 11.928 2.35E-91 7.56e-88

Chemical, Pharmacological and Biological Annotations


ATC Code:
L01BC02
Brands:
Carzonal (Tobishi); Efudix (Meda); Efurix (Valeant); Ftoruracil (Verofarm)
Categories:
Immunosuppressive Agents; Antimetabolites; Antimetabolites, Antineoplastic
ChEBI ID:
46345
PubChem ID:
3385
KEGG Drug ID:
D00584
SMILE:
FC1=CNC(=O)NC1=O
InChI:
1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
Classification:
Kingdom:
Organic Compounds
Superclass:
Heterocyclic Compounds
Class:
Diazines
Subclass:
Pyrimidines and Pyrimidine Derivatives
Indication:
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficu...
Click to show more...
Pharmacodynamics:
Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances from becoming incorporated into DNA during the "S" phase (of the...
Click to show more...
Description:
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]
Mechanism:
The precise mechanism of action has not been fully determined, but the main mechanism of fluorouracil is thought to be the binding of the deoxyribonucleotide of the drug (FdUMP) and the folate cofactor, N5–10-methylenetetrahydrofolate, to t...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
+
Caco-2 permeable:
-
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
2.2529 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org